Axcelead Drug Discovery Partners was rated as “Excellent” by Japan Agency for Medical Research and Development (AMED)* in a program for “Drug Discovery Seeds Development”

2021.11.25

Axcelead Drug Discovery Partners, Inc. (Axcelead DDP) has supported 24 research projects aiming at new drug development in an infrastructure program for “Drug Discovery Seeds Development ” since 2017. This program is one of initiatives in AMED to incubate drug discovery seeds originated in academic research organizations. In this program, Axcelead DDP has worked as “Innovation Engine Unit” which supports academia-originated projects at all drug discovery stages and provides consultations for the drug discovery programs to enhance attractiveness to pharmaceutical companies.

Axcelead DDP was rated as “Excellent” with the following comments: “Axcelead DDP has established sufficient drug discovery research platforms and support systems with drug discovery research experts. It is highly commendable that drug discovery support has been carried out with high quality and agility. Furthermore, their problem finding and solution provision made significant contributions to exploratory research and target validation studies in the early stages of drug discovery”. AMED gave an “Excellent” rating only to Axcelead DDP among 7 organizations participated in this project.

Yoshinori Ikeura, President and CEO of Axcelead DDP, said, “This project was initiated shortly after the establishment of Axcelead DDP in 2017. Axcelead DDP presents a founding vision to become a hub of the drug discovery ecosystem that bridges basic research to clinical application research. I remember vividly that all our employees were delighted to participate in this project which realizes our vision. In addition, I am proud that our drug discovery researchers have not only received such a wonderful evaluation but also contributed to the academia researchers in this project based on our vision. We go on strengthening and expanding the drug discovery platforms to continue offering higher quality drug discovery support.”

Notes
* AMED, The Japan Agency for Medical Research and Development (AMED) was established in 2015 for the advancement of medical discoveries that make life better for everyone.
https://www.amed.go.jp/en/aboutus/objectives_project.html

Contacts for Axcelead Drug Discovery Partners Inc.:
Sales and Marketing
+81-80-7005-5100
E-mail: info@axcelead.com
URL:     https://www.axcelead.com/en/